Financhill
Sell
44

OM Quote, Financials, Valuation and Earnings

Last price:
$17.73
Seasonality move :
-35.2%
Day range:
$17.29 - $19.90
52-week range:
$5.85 - $72.60
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.66x
P/B ratio:
1.88x
Volume:
253K
Avg. volume:
215.2K
1-year change:
-69.11%
Market cap:
$312.1M
Revenue:
$113.7M
EPS (TTM):
-$29.16

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
OM
Outset Medical
$27.8M -$0.95 7.36% -90.13% $24.00
BSX
Boston Scientific
$4.6B $0.67 18.78% 229.3% $116.96
IART
Integra Lifesciences Holdings
$381.2M $0.43 -5.53% 241.78% $16.13
PDEX
Pro-Dex
$17.7M $0.47 19.14% 4.44% $56.00
PODD
Insulet
$543.3M $0.79 25.35% -64.11% $332.35
SYK
Stryker
$5.7B $2.73 9.23% 43.28% $420.92
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
OM
Outset Medical
$17.61 $24.00 $312.1M -- $0.00 0% 0.66x
BSX
Boston Scientific
$104.50 $116.96 $154.6B 76.28x $0.00 0% 8.86x
IART
Integra Lifesciences Holdings
$12.68 $16.13 $985.4M 70.14x $0.00 0% 0.60x
PDEX
Pro-Dex
$40.35 $56.00 $131.6M 14.46x $0.00 0% 2.11x
PODD
Insulet
$323.85 $332.35 $22.8B 58.25x $0.00 0% 10.90x
SYK
Stryker
$382.35 $420.92 $146.1B 51.67x $0.84 0.86% 6.35x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
OM
Outset Medical
35.65% 2.513 47.09% 6.60x
BSX
Boston Scientific
33.49% 1.029 7.48% 0.68x
IART
Integra Lifesciences Holdings
54.74% 2.245 107.86% 0.57x
PDEX
Pro-Dex
34.14% 0.505 11.31% 1.41x
PODD
Insulet
56.03% 1.663 9.18% 3.24x
SYK
Stryker
44.5% 1.153 12.02% 0.80x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
OM
Outset Medical
$11.1M -$16.4M -44.16% -140.06% -74.31% -$25.8M
BSX
Boston Scientific
$3.2B $937M 6.35% 9.57% 19.02% $277M
IART
Integra Lifesciences Holdings
$194.4M -$15.5M -0.86% -1.88% -2.93% -$40.2M
PDEX
Pro-Dex
$5.8M $3.6M 20.23% 29.31% 27.56% $574K
PODD
Insulet
$409M $88.8M 15.79% 36.9% 10.07% $48.1M
SYK
Stryker
$3.7B $872M 8.33% 14.2% 14.87% $127M

Outset Medical vs. Competitors

  • Which has Higher Returns OM or BSX?

    Boston Scientific has a net margin of -86.66% compared to Outset Medical's net margin of 14.45%. Outset Medical's return on equity of -140.06% beat Boston Scientific's return on equity of 9.57%.

    Company Gross Margin Earnings Per Share Invested Capital
    OM
    Outset Medical
    37.19% -$3.66 $264M
    BSX
    Boston Scientific
    68.84% $0.45 $33.6B
  • What do Analysts Say About OM or BSX?

    Outset Medical has a consensus price target of $24.00, signalling upside risk potential of 36.29%. On the other hand Boston Scientific has an analysts' consensus of $116.96 which suggests that it could grow by 11.93%. Given that Outset Medical has higher upside potential than Boston Scientific, analysts believe Outset Medical is more attractive than Boston Scientific.

    Company Buy Ratings Hold Ratings Sell Ratings
    OM
    Outset Medical
    3 2 0
    BSX
    Boston Scientific
    23 3 0
  • Is OM or BSX More Risky?

    Outset Medical has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Boston Scientific has a beta of 0.685, suggesting its less volatile than the S&P 500 by 31.536%.

  • Which is a Better Dividend Stock OM or BSX?

    Outset Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Outset Medical pays -- of its earnings as a dividend. Boston Scientific pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios OM or BSX?

    Outset Medical quarterly revenues are $29.8M, which are smaller than Boston Scientific quarterly revenues of $4.7B. Outset Medical's net income of -$25.8M is lower than Boston Scientific's net income of $674M. Notably, Outset Medical's price-to-earnings ratio is -- while Boston Scientific's PE ratio is 76.28x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Outset Medical is 0.66x versus 8.86x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    OM
    Outset Medical
    0.66x -- $29.8M -$25.8M
    BSX
    Boston Scientific
    8.86x 76.28x $4.7B $674M
  • Which has Higher Returns OM or IART?

    Integra Lifesciences Holdings has a net margin of -86.66% compared to Outset Medical's net margin of -6.61%. Outset Medical's return on equity of -140.06% beat Integra Lifesciences Holdings's return on equity of -1.88%.

    Company Gross Margin Earnings Per Share Invested Capital
    OM
    Outset Medical
    37.19% -$3.66 $264M
    IART
    Integra Lifesciences Holdings
    50.81% -$0.33 $3.4B
  • What do Analysts Say About OM or IART?

    Outset Medical has a consensus price target of $24.00, signalling upside risk potential of 36.29%. On the other hand Integra Lifesciences Holdings has an analysts' consensus of $16.13 which suggests that it could grow by 27.17%. Given that Outset Medical has higher upside potential than Integra Lifesciences Holdings, analysts believe Outset Medical is more attractive than Integra Lifesciences Holdings.

    Company Buy Ratings Hold Ratings Sell Ratings
    OM
    Outset Medical
    3 2 0
    IART
    Integra Lifesciences Holdings
    2 5 2
  • Is OM or IART More Risky?

    Outset Medical has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Integra Lifesciences Holdings has a beta of 1.268, suggesting its more volatile than the S&P 500 by 26.765%.

  • Which is a Better Dividend Stock OM or IART?

    Outset Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Integra Lifesciences Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Outset Medical pays -- of its earnings as a dividend. Integra Lifesciences Holdings pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios OM or IART?

    Outset Medical quarterly revenues are $29.8M, which are smaller than Integra Lifesciences Holdings quarterly revenues of $382.7M. Outset Medical's net income of -$25.8M is lower than Integra Lifesciences Holdings's net income of -$25.3M. Notably, Outset Medical's price-to-earnings ratio is -- while Integra Lifesciences Holdings's PE ratio is 70.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Outset Medical is 0.66x versus 0.60x for Integra Lifesciences Holdings. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    OM
    Outset Medical
    0.66x -- $29.8M -$25.8M
    IART
    Integra Lifesciences Holdings
    0.60x 70.14x $382.7M -$25.3M
  • Which has Higher Returns OM or PDEX?

    Pro-Dex has a net margin of -86.66% compared to Outset Medical's net margin of 18.81%. Outset Medical's return on equity of -140.06% beat Pro-Dex's return on equity of 29.31%.

    Company Gross Margin Earnings Per Share Invested Capital
    OM
    Outset Medical
    37.19% -$3.66 $264M
    PDEX
    Pro-Dex
    33.3% $0.98 $53.6M
  • What do Analysts Say About OM or PDEX?

    Outset Medical has a consensus price target of $24.00, signalling upside risk potential of 36.29%. On the other hand Pro-Dex has an analysts' consensus of $56.00 which suggests that it could grow by 38.79%. Given that Pro-Dex has higher upside potential than Outset Medical, analysts believe Pro-Dex is more attractive than Outset Medical.

    Company Buy Ratings Hold Ratings Sell Ratings
    OM
    Outset Medical
    3 2 0
    PDEX
    Pro-Dex
    1 0 0
  • Is OM or PDEX More Risky?

    Outset Medical has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Pro-Dex has a beta of 0.365, suggesting its less volatile than the S&P 500 by 63.531%.

  • Which is a Better Dividend Stock OM or PDEX?

    Outset Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pro-Dex offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Outset Medical pays -- of its earnings as a dividend. Pro-Dex pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios OM or PDEX?

    Outset Medical quarterly revenues are $29.8M, which are larger than Pro-Dex quarterly revenues of $17.4M. Outset Medical's net income of -$25.8M is lower than Pro-Dex's net income of $3.3M. Notably, Outset Medical's price-to-earnings ratio is -- while Pro-Dex's PE ratio is 14.46x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Outset Medical is 0.66x versus 2.11x for Pro-Dex. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    OM
    Outset Medical
    0.66x -- $29.8M -$25.8M
    PDEX
    Pro-Dex
    2.11x 14.46x $17.4M $3.3M
  • Which has Higher Returns OM or PODD?

    Insulet has a net margin of -86.66% compared to Outset Medical's net margin of 6.22%. Outset Medical's return on equity of -140.06% beat Insulet's return on equity of 36.9%.

    Company Gross Margin Earnings Per Share Invested Capital
    OM
    Outset Medical
    37.19% -$3.66 $264M
    PODD
    Insulet
    71.88% $0.50 $3B
  • What do Analysts Say About OM or PODD?

    Outset Medical has a consensus price target of $24.00, signalling upside risk potential of 36.29%. On the other hand Insulet has an analysts' consensus of $332.35 which suggests that it could grow by 1.96%. Given that Outset Medical has higher upside potential than Insulet, analysts believe Outset Medical is more attractive than Insulet.

    Company Buy Ratings Hold Ratings Sell Ratings
    OM
    Outset Medical
    3 2 0
    PODD
    Insulet
    14 2 0
  • Is OM or PODD More Risky?

    Outset Medical has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Insulet has a beta of 1.263, suggesting its more volatile than the S&P 500 by 26.336%.

  • Which is a Better Dividend Stock OM or PODD?

    Outset Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Outset Medical pays -- of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios OM or PODD?

    Outset Medical quarterly revenues are $29.8M, which are smaller than Insulet quarterly revenues of $569M. Outset Medical's net income of -$25.8M is lower than Insulet's net income of $35.4M. Notably, Outset Medical's price-to-earnings ratio is -- while Insulet's PE ratio is 58.25x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Outset Medical is 0.66x versus 10.90x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    OM
    Outset Medical
    0.66x -- $29.8M -$25.8M
    PODD
    Insulet
    10.90x 58.25x $569M $35.4M
  • Which has Higher Returns OM or SYK?

    Stryker has a net margin of -86.66% compared to Outset Medical's net margin of 11.15%. Outset Medical's return on equity of -140.06% beat Stryker's return on equity of 14.2%.

    Company Gross Margin Earnings Per Share Invested Capital
    OM
    Outset Medical
    37.19% -$3.66 $264M
    SYK
    Stryker
    63.83% $1.69 $37.7B
  • What do Analysts Say About OM or SYK?

    Outset Medical has a consensus price target of $24.00, signalling upside risk potential of 36.29%. On the other hand Stryker has an analysts' consensus of $420.92 which suggests that it could grow by 10.09%. Given that Outset Medical has higher upside potential than Stryker, analysts believe Outset Medical is more attractive than Stryker.

    Company Buy Ratings Hold Ratings Sell Ratings
    OM
    Outset Medical
    3 2 0
    SYK
    Stryker
    13 9 0
  • Is OM or SYK More Risky?

    Outset Medical has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Stryker has a beta of 0.929, suggesting its less volatile than the S&P 500 by 7.091%.

  • Which is a Better Dividend Stock OM or SYK?

    Outset Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stryker offers a yield of 0.86% to investors and pays a quarterly dividend of $0.84 per share. Outset Medical pays -- of its earnings as a dividend. Stryker pays out 40.73% of its earnings as a dividend. Stryker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios OM or SYK?

    Outset Medical quarterly revenues are $29.8M, which are smaller than Stryker quarterly revenues of $5.9B. Outset Medical's net income of -$25.8M is lower than Stryker's net income of $654M. Notably, Outset Medical's price-to-earnings ratio is -- while Stryker's PE ratio is 51.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Outset Medical is 0.66x versus 6.35x for Stryker. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    OM
    Outset Medical
    0.66x -- $29.8M -$25.8M
    SYK
    Stryker
    6.35x 51.67x $5.9B $654M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Where Will Cameco Stock Be in 5 Years?
Where Will Cameco Stock Be in 5 Years?

Cameco (NYSE: CCJ) isn’t exactly the kind of stock you…

Microsoft Stock Outlook, Azure & AI as Drivers of Long-Term Growth
Microsoft Stock Outlook, Azure & AI as Drivers of Long-Term Growth

Microsoft (NASDAQ:MSFT) has been among the top growth stocks of…

Is Tesla Stock Overvalued or a Buy for the Next Decade?
Is Tesla Stock Overvalued or a Buy for the Next Decade?

Shares of EV major Tesla (NASDAQ:TSLA) have experienced extreme volatility…

Stock Ideas

Buy
67
Is MSFT Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 39x

Buy
70
Is NVDA Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 47x

Sell
39
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 33x

Alerts

Buy
84
SBET alert for May 30

SharpLink Gaming [SBET] is up 181.07% over the past day.

Buy
55
RGC alert for May 30

Regencell Bioscience Holdings [RGC] is up 42.55% over the past day.

Buy
73
CTEV alert for May 30

Claritev [CTEV] is up 34.96% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock